• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Glimepiride Teva
    / Abic


    Active Ingredient
    Glimepiride 1 mg, 2 mg, 3 mg, 4 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 X 1 mg

    partial basket chart 53400 7912

    Tablets

    30 X 2 mg

    partial basket chart 53405 7913

    Tablets

    30 X 3 mg

    partial basket chart 53407 7914

    Tablets

    30 X 4 mg

    partial basket chart 53409 7915

    Related information


    Dosage

    Usual starting dose is 1-2 mg once daily, administered with breakfast. The dose may be increased as needed. Maximum daily dose: 8 mg.


    Indications

    Non-insulin-dependent diabetes melitus (adult-onset diabetes, type II diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.


    Contra-Indications

    – You are sensitive (allergic) to the active ingredient, or to any of the additional ingredients contained in the medicine.
    – You are sensitive to other derivatives of sulfonylurea or to sulfonamides.
    – You may also develop an allergy to this medicine. Signs of an allergic reaction include skin reactions and severe effects, such as shortness of breath, decreased blood pressure or anaphylactic shock.
    – This medicine is not intended to treat type 1 diabetes, severe or unstable diabetes, ketosis or acidosis as a complication of diabetes, or diabetic coma.


    Special Precautions

    Refer to the package information leaflet.


    Side Effects

    Refer to the package information leaflet.


    Drug interactions

    Refer to the package information leaflet.


    Pregnancy and Lactation

    Refer to the package information leaflet.


    Overdose

    Refer to the package information leaflet.


    Important notes

    Refer to the package information leaflet.


    Manufacturer
    Teva Hungary
    CLOSE